Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China.
Shanghai ChemPartner Co., LTD, Shanghai, China.
PLoS One. 2014 Jan 9;9(1):e85308. doi: 10.1371/journal.pone.0085308. eCollection 2014.
Hepatocellular carcinoma (HCC) is a common cancer with poor prognosis worldwide and the molecular mechanism is not well understood. This study aimed to establish a collection of human HCC cell lines from patient-derived xenograft (PDX) models. From the 20 surgical HCC sample collections, 7 tumors were successfully developed in immunodeficient mice and further established 7 novel HCC cell lines (LIXC002, LIXC003, LIXC004, LIXC006, LIXC011, LIXC012 and CPL0903) by primary culture. The characterization of cell lines was defined by morphology, growth kinetics, cell cycle, chromosome analysis, short tandem repeat (STR) analysis, molecular profile, and tumorigenicity. Additionally, response to clinical chemotherapeutics was validated both in vitro and in vivo. STR analysis indicated that all cell lines were unique cells different from known cell lines and free of contamination by bacteria or mycoplasma. The other findings were quite heterogeneous between individual lines. Chromosome aberration could be found in all cell lines. Alpha-fetoprotein was overexpressed only in 3 out of 7 cell lines. 4 cell lines expressed high level of vimentin. Ki67 was strongly stained in all cell lines. mRNA level of retinoic acid induced protein 3 (RAI3) was decreased in all cell lines. The 7 novel cell lines showed variable sensitivity to 8 tested compounds. LIXC011 and CPL0903 possessed multiple drug resistance property. Sorafenib inhibited xenograft tumor growth of LIXC006, but not of LIXC012. Our results indicated that the 7 novel cell lines with low passage maintaining their clinical and pathological characters could be good tools for further exploring the molecular mechanism of HCC and anti-cancer drug screening.
肝细胞癌(HCC)是一种常见的癌症,全球预后不良,其分子机制尚不清楚。本研究旨在建立一组来自患者来源的异种移植(PDX)模型的人 HCC 细胞系。在 20 个外科 HCC 样本采集物中,有 7 个肿瘤在免疫缺陷小鼠中成功发育,并通过原代培养进一步建立了 7 种新型 HCC 细胞系(LIXC002、LIXC003、LIXC004、LIXC006、LIXC011、LIXC012 和 CPL0903)。通过形态学、生长动力学、细胞周期、染色体分析、短串联重复(STR)分析、分子谱和致瘤性对细胞系进行了特征描述。此外,还在体外和体内验证了对临床化疗药物的反应。STR 分析表明,所有细胞系均为与已知细胞系不同的独特细胞,且无细菌或支原体污染。其他发现则在个体系之间存在较大的异质性。所有细胞系均存在染色体异常。7 个细胞系中有 3 个 AFP 过表达。4 个细胞系高表达波形蛋白。所有细胞系 Ki67 均强烈染色。所有细胞系的维甲酸诱导蛋白 3(RAI3)mRNA 水平降低。7 种新型细胞系对 8 种测试化合物的敏感性不同。LIXC011 和 CPL0903 具有多药耐药性。索拉非尼抑制 LIXC006 的异种移植肿瘤生长,但不抑制 LIXC012。我们的结果表明,这 7 种新型细胞系传代低,保持其临床和病理特征,可作为进一步探索 HCC 分子机制和抗癌药物筛选的良好工具。